All News

Article

EULAR 2021 – Day 1 Report

Jack Cush, MD

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Janet Pope Tweet
Janetbirdope
Can machine learning show JAKi effects for safety? Off target binding predicted in #tofacitinib 58, #baricitinib 41 but NO pathway for thrombosis or viral infection. Could have repurposing for + effects on lung vasculature & antifibrotic effects POS0091 #EULAR2021 @RheumNow
Janet Pope Tweet
Janetbirdope
MACE events with #JAKi is as clear as mud! You voted >50% NOT Sure 1/3 only some Jakis vs MACE in #TNFi! Dunno #EULAR2021 @RheumNow @eular_org https://t.co/vWUgKSwAap
Janet Pope Tweet
Janetbirdope
How common is RA ILD? @RheumNow #EULAR2021 @eular_org
Janet Pope Tweet
Janetbirdope
RA ILD is NOT a needle in a haystack! Older age& makes & COPD is a risk MUC5B gene SNIP are risks NOT ACPA. 7-10% will have relevant RA ILD. Are you ready to identity & treat it? @RheumNow #EULAR2021 BI RA ILD symposium @eular_org https://t.co/4mS6Jejjqk
Janet Pope Tweet
Janetbirdope
Leave my MTX alone says pt & #rheumatologist if pt has chronic ILD. Acute pneumonia from MTX is NOT chronic ILD in RA @RheumNow @eular_org #EULAR2021 #BoehringerIngelheim RA ILD silent killer symposium https://t.co/IQTINuUpVq
Richard Conway Tweet
RichardPAConway
Great talks on comorbidities in RA at #EULAR2021 today. What do we struggle most with in RA management? @RheumNow
Janet Pope Tweet
Janetbirdope
RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg
Paul Studenic Tweet
Stiddyo
#POS0093 Collaborative registry studies are to be encouraged! BUT @k_lauper outlines the heterogenity between registries concerning #AE reporting - Jak-pot study - 18 registries with #RA patients on #tofacitinib - Rates of discontinuation vary across registry #EULAR2021 @RheumNow https://t.co/oczJAG8hzv
Aurelie Najm Tweet
AurelieRheumo
An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
Janet Pope Tweet
Janetbirdope
What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Prednisone are Impt. Piling up risk factors is often multiplied! Biggest risk of serious infection and is recurrent serious infection! #EULAR2021 Meet the expert AbbVie session @RheumNow https://t.co/6m0OfsNF1W
ARD & RMD Open Tweet
ARD_BMJ
MUC5B promoter variant is associated with interstitial lung disease. Interactions with: 👉rheumatoid arthritis 👉 age 👉 sex Check this Finnish biobank study of 250,000 individuals presented by Antti Palömaki at the Plenary Abstracts Session Wed 02/06 16:15 >LC
Dr Irwin Lim Tweet
_connectedcare
Patients selected to maximise response & minimise adverse events in RA & PsA trials. What implications does this have when we interpret the data & try to apply in clinic? #EULAR2021 https://t.co/CocKlvjme4
David Liew Tweet
drdavidliew
Worse dentition is associated with worse RA disease activity. And that's the tooth!🙄 from two big German cohorts @CallhoffJ POS0026 #EULAR2021 @RheumNow https://t.co/rjCQ6AtQzq
EMEUNET Tweet
EMEUNET
After this morning's great discussion at the #epidemiology interest group, Prof Nagy gives a summary of the @eular_org Definition of difficult-to-treat #RheumatoidArthritis at #EULAR2021, including a great summary of the elements and evidence behind the recommendation. https://t.co/imXECTlUbf
×